纽福斯（上海）生物科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S. 2024-02-19 19:30
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy 2023-08-17 21:00
Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials 2023-08-11 21:00
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON 2023-02-21 21:30
Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON 2022-12-19 21:00
Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day 2022-10-13 20:30
Neurophth announces first patient dosed in Phase III clinical trial for the gene therapy treatment of LHON 2022-09-27 20:30
Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day 2022-09-19 20:00
China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON 2022-07-15 21:00
The 3rd BIO International Convention 2022 is Approaching 2022-06-07 19:23
Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer 2022-06-02 21:00
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA 2022-01-25 22:00
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy 2022-01-19 22:30
Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer 2021-11-24 21:30
Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies 2021-11-23 21:30
Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards 2021-09-27 23:00
Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial 2021-08-19 22:00
First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON 2021-06-28 21:33
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases 2021-06-01 19:50
Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy 2021-04-01 20:39
1 2